CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Salix Pharmaceuticals, Ltd. is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Salix Pharmaceuticals, Ltd.
8510 Colonnade Center Drive
Phone: (919) 862-1000p:919 862-1000 Raleigh, NC  27615-3050  United States Ticker: SLXPSLXP
This company was Merged or Acquired on 4/1/2015.
This company ceased filing statements with the SEC on 4/13/2015.
This company is no longer actively traded on any major stock exchange.
This is a Subsidiary, click here for the Parent Company
Business Summary
Salix Pharmaceuticals, Ltd. is a specialty pharmaceutical company engaged in the prevention and treatment of gastrointestinal (GI) disorders. The Company’s products are APRISO (mesalamine) indicated for the maintenance of remission of ulcerative colitis; COLAZAL (balsalazide disodium), treats mildly to moderately active ulcerative colitis, a form of inflammatory bowel disease with symptoms including bloody diarrhea and rectal bleeding; FULYZAQ (crofelemer) is an anti-diarrheal indicated for the symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS on anti-retroviral therapy; GIAZO (balsalazide disodium) is indicated for the treatment of mildly to moderately active ulcerative colitis (UC) in male patients 18 years of age and older; METOZOLV (metoclopramide HCl) ODT is orally disintegrating metoclopramide tablet, indicated for the relief of symptoms associated with acute and recurrent diabetic gastroparesis (gastric stasis) in adults; among others.
(Source: Company's Website)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/201412/31/2014YesYes--Yes

Industries
SIC Code Description
2834 Pharmaceutical preparations
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board, Acting President and Chief Executive Officer Thomas W.D'Alonzo 71 1/30/2015 5/1/2000
Acting Chief Financial Officer Timothy J.Creech 51 11/6/2014 11/6/2014
President - Medical, Research and Development and Chief Development Officer William P.Forbes 53 2/2/2015 1/10/2005
5 additional Officers and Directors records available in full report.

Business Names
Business Name
Oceana Therapeutics, Inc.
Salix Pharmaceuticals, Inc.
Santarus, Inc.
SLXP

General Information
Number of Employees: 1,000 (As of 12/31/2014)
Outstanding Shares: 64,248,533 (As of 2/24/2015)
Shareholders: 220
Stock Exchange: NASD
Federal Tax Id: 943267443
Fax Number: (919) 862-1095
Email Address: investor.relations@salixpharm.com


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, July 21, 2023